Trials / Completed
CompletedNCT05415462
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
A Phase 3, Randomized, Stratified, Observer-blind, Active-Controlled Study to Evaluate the Immunogenicity and Safety of mRNA-1010 Seasonal Influenza Vaccine in Adults 18 Years and Older
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 6,102 (actual)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The primary objectives of this study are to evaluate the humoral immunogenicity of mRNA-1010 relative to that of an active comparator against vaccine-matched influenza A and B strains at Day 29, and to evaluate the safety and reactogenicity of mRNA-1010.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | mRNA-1010 | Sterile liquid for injection |
| BIOLOGICAL | Fluarix Tetra | Sterile suspension for injection |
Timeline
- Start date
- 2022-06-06
- Primary completion
- 2023-09-04
- Completion
- 2023-09-04
- First posted
- 2022-06-13
- Last updated
- 2024-09-24
- Results posted
- 2024-09-24
Locations
53 sites across 5 countries: Argentina, Australia, Colombia, Panama, Philippines
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05415462. Inclusion in this directory is not an endorsement.